NCT06151561View on ClinicalTrials.gov

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

April 3, 2024

Study Completion Date

April 3, 2024

Conditions
Moderate to Severe Glabellar Lines
Interventions
DRUG

AGN-151586

Intramuscular Injection

DRUG

Placebo

Intramuscular Injection

Trial Locations (1)

103-0028

Tokyo Center Clinic /ID# 257898, Central District

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY